BNP Paribas Financial Markets Sells 168,786 Shares of IQVIA Holdings Inc. $IQV

Key Points

• BNP Paribas Financial Markets has sold 35.4% of its stake in IQVIA Holdings Inc., reducing its ownership to approximately 307,656 shares valued at $54.24 million.
• Recent analyst reports have led to a variety of target price updates for IQVIA, with JPMorgan lowering its target from $232 to $177, while Barclays increased theirs from $165 to $185.
• IQVIA's quarterly earnings topped analysts' expectations, reporting $2.81 EPS and a revenue of $4.02 billion, indicating a 5.3% increase year-over-year.

BNP Paribas Financial Markets lessened its stake in IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 35.4% during the 1st quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 307,656 shares of the medical research company's stock after selling 168,786 shares during the quarter. BNP Paribas Financial Markets owned 0.18% of IQVIA worth $54,240,000 at the end of the most recent reporting period.

Several other large investors have also recently added to or reduced their stakes in IQV. American National Bank & Trust acquired a new position in IQVIA in the 1st quarter valued at approximately $26,000. Clal Insurance Enterprises Holdings Ltd grew its position in IQVIA by 436.7% in the first quarter. Clal Insurance Enterprises Holdings Ltd now owns 161 shares of the medical research company's stock worth $28,000 after acquiring an additional 131 shares in the last quarter. Golden State Wealth Management LLC grew its position in IQVIA by 295.5% in the first quarter. Golden State Wealth Management LLC now owns 174 shares of the medical research company's stock worth $31,000 after acquiring an additional 130 shares in the last quarter. AllSquare Wealth Management LLC bought a new stake in IQVIA in the first quarter worth approximately $33,000. Finally, ST Germain D J Co. Inc. grew its position in IQVIA by 66.1% in the first quarter. ST Germain D J Co. Inc. now owns 191 shares of the medical research company's stock worth $34,000 after acquiring an additional 76 shares in the last quarter. Institutional investors and hedge funds own 89.62% of the company's stock.

Wall Street Analysts Forecast Growth

Several analysts have commented on IQV shares. JPMorgan Chase & Co. decreased their target price on shares of IQVIA from $232.00 to $177.00 and set an "overweight" rating for the company in a research report on Monday, May 19th. Cowen reissued a "buy" rating on shares of IQVIA in a research report on Wednesday, July 23rd. Redburn Partners set a $214.00 target price on shares of IQVIA in a research report on Wednesday. UBS Group upped their price objective on shares of IQVIA from $185.00 to $225.00 and gave the stock a "buy" rating in a report on Wednesday, July 23rd. Finally, Citigroup reaffirmed a "neutral" rating on shares of IQVIA in a report on Thursday, May 22nd. Seventeen equities research analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $229.86.

IQVIA Price Performance

Shares of IQV stock traded down $0.28 during mid-day trading on Thursday, reaching $184.34. The company's stock had a trading volume of 681,087 shares, compared to its average volume of 1,924,522. IQVIA Holdings Inc. has a 1-year low of $134.65 and a 1-year high of $249.54. The company has a market cap of $31.34 billion, a P/E ratio of 26.60, a PEG ratio of 2.09 and a beta of 1.32. The company has a debt-to-equity ratio of 2.45, a quick ratio of 0.84 and a current ratio of 0.84. The firm's 50-day moving average is $178.75 and its two-hundred day moving average is $167.71.

IQVIA (NYSE:IQV - Get Free Report) last announced its quarterly earnings data on Tuesday, July 22nd. The medical research company reported $2.81 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $2.77 by $0.04. IQVIA had a net margin of 7.88% and a return on equity of 30.05%. The company had revenue of $4.02 billion during the quarter, compared to analysts' expectations of $3.96 billion. During the same quarter in the prior year, the company posted $2.64 EPS. The business's revenue was up 5.3% on a year-over-year basis. IQVIA has set its FY 2025 guidance at 11.750-12.050 EPS. On average, research analysts predict that IQVIA Holdings Inc. will post 10.84 earnings per share for the current year.

Insiders Place Their Bets

In related news, insider Keriann Cherofsky sold 549 shares of the stock in a transaction dated Wednesday, July 23rd. The shares were sold at an average price of $191.53, for a total transaction of $105,149.97. Following the completion of the sale, the insider owned 2,910 shares in the company, valued at $557,352.30. This trade represents a 15.87% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, insider Eric Sherbet sold 5,800 shares of the stock in a transaction dated Wednesday, July 23rd. The stock was sold at an average price of $190.05, for a total transaction of $1,102,290.00. Following the sale, the insider owned 27,178 shares of the company's stock, valued at $5,165,178.90. This trade represents a 17.59% decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 1.60% of the company's stock.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.